Hyperactive Delirium Clinical Trial
Official title:
A Pilot Study of the Psychometric Properties of the "Stanford Proxy Test for Delirium" (S-PTD): a New Screening Tool for the Detection of Delirium
NCT number | NCT03954769 |
Other study ID # | 28327 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | February 2014 |
Est. completion date | May 2016 |
Verified date | April 2019 |
Source | Stanford University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Although there are several tools available for the screening of delirium among the medically
ill, they all have some limitations. First, none of the available tools have been validated
against newly developed and published DSM-5 (Diagnostic and Statistical Manual) or ICD-10
(International Statistical Classification of Diseases and Related Health Problems) criteria.
Additionally, all the screening/diagnostic tools presently available have the same
limitation, they all require significant patient involvement and participation (e.g.,
questions and activities) in order to complete the assessment. By definition, delirium is a
neuropsychiatric disorder characterized by disturbance in attention and awareness, and
additional disturbance in cognition (e.g., memory deficit, disorientation), language,
visuospatial ability, or perception. The intrinsic characteristics of delirium seem to
interfere with the patient's ability to participate and complete many of the tasks associated
with delirium evaluation itself. Finally, most available tools seem to narrowly focus on some
neurocognitive areas of delirium, but not being comprehensive enough.
In contrast, the S-PTD is designed so it can be completed by the nursing staff caring for the
patients, the medical personnel most intimately involved with the care and aware of the
behaviors exhibited by the patient during the course of their hospital stay. The idea is that
nurses will complete the screening tool (hence the term "by proxy"), based on the behaviors
and interactions observed during the course of a conventional "nursing shift", to determine
whether the patient meets current neuropsychiatric criteria for the diagnosis of delirium.
Status | Completed |
Enrollment | 300 |
Est. completion date | May 2016 |
Est. primary completion date | January 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Inclusion criteria for enrolled patients: - all inpatients admitted to Stanford Hospital's selected general medical and surgical units - patients must be able to communicate and read English and/or Spanish - ages 18 and older - Inclusion criteria for enrolled nurses: - All nurses assigned to each enrolled patient for the shift during which that patient is enrolled, will be invited to participate in the study to assess the tool's acceptability and ease of use. Exclusion Criteria: - For enrolled patients: - unable to speak English or Spanish. - unwillingness to participate in the study - for patients who are unable to consent (i.e., lack capacity), either the lack of availability of a suitable surrogate or the surrogate's unwillingness to provide consent - For enrolled nurses: unwillingness to participate in the study. |
Country | Name | City | State |
---|---|---|---|
United States | Stanford Hospital and Clinics | Stanford | California |
Lead Sponsor | Collaborator |
---|---|
Stanford University |
United States,
Maldonado JR. Delirium in the acute care setting: characteristics, diagnosis and treatment. Crit Care Clin. 2008 Oct;24(4):657-722, vii. doi: 10.1016/j.ccc.2008.05.008. Review. — View Citation
Nørbæk J, Glipstrup E. Delirium is seen in one-third of patients in an acute hospital setting. Identification, pharmacologic and non-pharmacologic treatment is inadequate. Dan Med J. 2016 Nov;63(11). pii: A5293. — View Citation
Ryan DJ, O'Regan NA, Caoimh RÓ, Clare J, O'Connor M, Leonard M, McFarland J, Tighe S, O'Sullivan K, Trzepacz PT, Meagher D, Timmons S. Delirium in an adult acute hospital population: predictors, prevalence and detection. BMJ Open. 2013 Jan 7;3(1). pii: e001772. doi: 10.1136/bmjopen-2012-001772. — View Citation
Siddiqi N, House AO, Holmes JD. Occurrence and outcome of delirium in medical in-patients: a systematic literature review. Age Ageing. 2006 Jul;35(4):350-64. Epub 2006 Apr 28. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of delirium | Every day, enrolled patients will undergo two evaluations: (1) At the end of the nursing shift, nurses will complete the S-PTD based on the entirety of the interactions with the patient throughout the course of their shift, estimated to take about 2-3 minutes; (2) then, within 1-hour of the nurse's S-PTD assessment a member of the Psychosomatic Medicine Service will conduct a blinded clinical neuropsychiatric examination (the gold standard for delirium diagnosis). At the end of their nursing shift (either 8 or 12 hours). | The study will be carried out over a 2-year period; patients will be followed throughout the hospital stay, for a maximum of 2-weeks from the time of admission, or until discharge. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03621228 -
MindfulGarden in Treatment of Hyperactive Delirium in a Hospital Setting
|
N/A | |
Recruiting |
NCT03215745 -
Delirium Prevention in Patients From the Intensive Care Unit (DELA)
|
N/A | |
Recruiting |
NCT04824144 -
Effects of Dexmedetomidine in Patients With Agitated Delirium in Palliative Care
|
Phase 1/Phase 2 | |
Recruiting |
NCT04833023 -
HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial
|
Phase 3 | |
Withdrawn |
NCT04513314 -
Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated Delirium
|
Phase 4 | |
Terminated |
NCT02343575 -
Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU
|
Phase 4 | |
Completed |
NCT05690698 -
Quetiapine Versus Haloperidol in the Management of Hyperactive Delirium
|
Phase 3 |